PharmChem, Inc. (PCHM)
USD 3.05
(0.0%)
USD 3.05
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 558.64 Thousand USD | 24.91% |
| 2022 | 447.22 Thousand USD | -17.56% |
| 2021 | 542.45 Thousand USD | -52.47% |
| 2020 | 1.14 Million USD | 45.32% |
| 2019 | 785.27 Thousand USD | 5.52% |
| 2018 | 744.17 Thousand USD | 13.1% |
| 2017 | 658 Thousand USD | 11.75% |
| 2016 | 588.81 Thousand USD | 0.0% |
| 2002 | 12.3 Million USD | -43.43% |
| 2001 | 21.75 Million USD | 77.33% |
| 2000 | 12.27 Million USD | 8.12% |
| 1999 | 11.34 Million USD | 1.76% |
| 1998 | 11.15 Million USD | -6.8% |
| 1997 | 11.96 Million USD | 17.54% |
| 1996 | 10.18 Million USD | -9.1% |
| 1995 | 11.2 Million USD | 6.67% |
| 1994 | 10.5 Million USD | -7.08% |
| 1993 | 11.3 Million USD | 14.14% |
| 1992 | 9.9 Million USD | 115.22% |
| 1991 | 4.6 Million USD | 15.0% |
| 1990 | 4 Million USD | 33.33% |
| 1989 | 3 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 574.78 Thousand USD | 2.89% |
| 2024 Q2 | 640.52 Thousand USD | 11.44% |
| 2023 FY | 558.64 Thousand USD | 24.91% |
| 2023 Q1 | 442.84 Thousand USD | -0.98% |
| 2023 Q2 | 621.61 Thousand USD | 40.37% |
| 2023 Q3 | 682.75 Thousand USD | 9.84% |
| 2023 Q4 | 558.64 Thousand USD | -18.18% |
| 2022 FY | 447.22 Thousand USD | -17.56% |
| 2022 Q2 | 433.26 Thousand USD | -7.16% |
| 2022 Q4 | 447.22 Thousand USD | 3.33% |
| 2022 Q1 | 466.66 Thousand USD | -13.97% |
| 2022 Q3 | 432.8 Thousand USD | -0.11% |
| 2021 Q2 | 649.52 Thousand USD | 0.0% |
| 2021 Q4 | 542.45 Thousand USD | -25.42% |
| 2021 FY | 542.45 Thousand USD | -52.47% |
| 2021 Q3 | 727.39 Thousand USD | 11.99% |
| 2020 FY | 1.14 Million USD | 45.32% |
| 2019 FY | 785.27 Thousand USD | 5.52% |
| 2018 FY | 744.17 Thousand USD | 13.1% |
| 2017 FY | 658 Thousand USD | 11.75% |
| 2016 FY | 588.81 Thousand USD | 0.0% |
| 2003 Q1 | 11.2 Million USD | -8.98% |
| 2003 Q2 | 10.78 Million USD | -3.78% |
| 2003 Q3 | 9.09 Million USD | -15.6% |
| 2002 Q4 | 12.3 Million USD | -8.22% |
| 2002 Q1 | 16.88 Million USD | -22.42% |
| 2002 FY | 12.3 Million USD | -43.43% |
| 2002 Q2 | 14.19 Million USD | -15.94% |
| 2002 Q3 | 13.41 Million USD | -5.49% |
| 2001 FY | 21.75 Million USD | 77.33% |
| 2001 Q2 | 18.76 Million USD | 41.06% |
| 2001 Q3 | 22.26 Million USD | 18.66% |
| 2001 Q4 | 21.75 Million USD | -2.29% |
| 2001 Q1 | 13.3 Million USD | 8.43% |
| 2000 Q2 | 12.13 Million USD | 5.83% |
| 2000 Q4 | 12.27 Million USD | 0.6% |
| 2000 FY | 12.27 Million USD | 8.12% |
| 2000 Q1 | 11.46 Million USD | 1.03% |
| 2000 Q3 | 12.19 Million USD | 0.52% |
| 1999 Q3 | 12.2 Million USD | 2.52% |
| 1999 FY | 11.34 Million USD | 1.76% |
| 1999 Q4 | 11.34 Million USD | -6.98% |
| 1999 Q2 | 11.9 Million USD | 7.21% |
| 1999 Q1 | 11.1 Million USD | -0.48% |
| 1998 Q4 | 11.15 Million USD | -10.06% |
| 1998 FY | 11.15 Million USD | -6.8% |
| 1998 Q3 | 12.4 Million USD | -7.46% |
| 1998 Q2 | 13.4 Million USD | 12.61% |
| 1998 Q1 | 11.9 Million USD | -0.56% |
| 1997 Q3 | 12.1 Million USD | 8.04% |
| 1997 Q1 | 9.3 Million USD | -8.65% |
| 1997 FY | 11.96 Million USD | 17.54% |
| 1997 Q2 | 11.2 Million USD | 20.43% |
| 1997 Q4 | 11.96 Million USD | -1.1% |
| 1996 FY | 10.18 Million USD | -9.1% |
| 1996 Q2 | 11.8 Million USD | 0.0% |
| 1996 Q4 | 10.18 Million USD | -5.73% |
| 1996 Q3 | 10.8 Million USD | -8.47% |
| 1996 Q1 | 11.8 Million USD | 5.36% |
| 1995 FY | 11.2 Million USD | 6.67% |
| 1995 Q4 | 11.2 Million USD | -11.11% |
| 1995 Q1 | 10.4 Million USD | -0.95% |
| 1995 Q3 | 12.6 Million USD | 0.0% |
| 1994 Q4 | 10.5 Million USD | 1.94% |
| 1994 Q3 | 10.3 Million USD | 0.0% |
| 1994 Q1 | 11.3 Million USD | 0.0% |
| 1994 FY | 10.5 Million USD | -7.08% |
| 1993 FY | 11.3 Million USD | 14.14% |
| 1993 Q2 | 8.8 Million USD | 0.0% |
| 1993 Q3 | 8.2 Million USD | -6.82% |
| 1993 Q4 | 11.3 Million USD | 37.8% |
| 1992 Q4 | 9.9 Million USD | 0.0% |
| 1992 FY | 9.9 Million USD | 115.22% |
| 1991 FY | 4.6 Million USD | 15.0% |
| 1991 Q4 | 4.6 Million USD | 0.0% |
| 1990 Q4 | 4 Million USD | 0.0% |
| 1990 FY | 4 Million USD | 33.33% |
| 1989 FY | 3 Million USD | 0.0% |
| 1989 Q4 | 3 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| American Bio Medica Corporation | 3.6 Million USD | 84.516% |
| Arrayit Corporation | 7.49 Million USD | 92.548% |
| Atlantic International Corp. | 3.82 Million USD | 85.409% |
| Biocept, Inc. | 22.01 Million USD | 97.462% |
| Bioqual, Inc. | 18.93 Million USD | 97.05% |
| CardioGenics Holdings Inc | 1.79 Million USD | 68.876% |
| DermTech, Inc. | 64.75 Million USD | 99.137% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 734.97 Million USD | 99.924% |
| HTG Molecular Diagnostics, Inc. | 12.38 Million USD | 95.49% |
| iMD Companies, Inc. | 1.67 Million USD | 66.632% |
| IDenta Corp. | 1.01 Million USD | 44.861% |
| Interpace Biosciences, Inc. | 28.15 Million USD | 98.016% |
| Integrative Health Technologies, Inc. | 297.94 Thousand USD | -87.499% |
| InVitro International | 78.99 Thousand USD | -607.238% |
| Lumos Diagnostics Holdings Limited | 19.72 Million USD | 97.168% |
| Many Bright Ideas Technologies Inc. | 129.29 Thousand USD | -332.065% |
| Medical Imaging Corp. | 9.51 Million USD | 94.13% |
| NovelStem International Corp. | 4.2 Million USD | 86.718% |
| Optigenex Inc. | 9.57 Million USD | 94.163% |
| Proteome Sciences plc | 18.48 Million USD | 96.978% |
| Response Genetics, Inc | 15.86 Million USD | 96.479% |
| Rennova Health, Inc. | 49.66 Million USD | 98.875% |
| RushNet, Inc. | 6.23 Million USD | 91.046% |
| ScreenPro Security Inc. | 1.6 Million USD | 65.097% |
| Stella Diagnostics Inc. | 18 Million USD | 96.897% |
| StageZero Life Sciences Ltd. | 8.2 Million USD | 93.191% |
| Todos Medical Ltd. | 50.15 Million USD | 98.886% |